225Ac-RYZ-801
- Generic Name
- 225Ac-RYZ-801
Study of the Theranostic Pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to Identify and Treat Subjects with GPC3+ Unresectable HCC
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- RayzeBio, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT06726161
- Locations
- 🇺🇸
Research Facility, Grand Rapids, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath